FDA Approves New Dog Anxiety Treatment for U.S. Market

Orion Corporation has announced that the U.S. Food and Drug Administration has approved Tessie, an oral solution for treating noise aversion and separation anxiety in dogs.

The approval was granted on May 6, 2026, for Tessie, also known as tasipimidine oral solution, developed by Orion Corporation through its animal health division.

The company said tasipimidine is a proprietary veterinary medicine and a new active substance for animal use in the United States. It works by acting on the central nervous system to reduce the startle reflex and calm dogs during stressful situations such as loud noises or separation from owners.

Executive Vice President of [Orion Animal Health](https://www.orionpharma.com/animal-health/?utm_source=chatgpt.com), Niclas Lindstedt, said the approval expands the company’s veterinary medicine portfolio aimed at meeting animal health needs.

Orion’s U.S. marketing partner, Zoetis has exclusive rights to sell Tessie in the country. The product is expected to be available in the U.S. by mid-2027 and will join the company’s existing animal behavioural treatment products, including Sileo and Bonqat.